Answers are grounded in this paper and cite their sources.
Background The outer membrane of Gram-negative bacteria restricts access of most exogenously applied endolysins to peptidoglycan. This study aimed to engineer ArtE2 from Bacillus altitudinis Endolysin-2 (E2) by fusing the polycationic decapeptide MKRKKRKKRK to the N-terminus and introducing the substitutions H176Y and T178R, and to evaluate its antibacterial activity against Escherichia coli while determining whether activity against Staphylococcus aureus was retained. Results ArtE2 was obtained as a soluble, highly cationic protein. Molecular docking predicted interactions with several peptidoglycan fragments, including the NAG–NAM dimer. ArtE2 displayed concentration- and time-dependent antibacterial activity against both E. coli ATCC 25922 and S. aureus ATCC 25923, whereas native E2 showed little activity against E. coli. Measurable residual activity was retained across the temperature and pH ranges examined. Molecular dynamics simulations revealed condition-dependent differences in RMSD, with comparatively low values under selected conditions, including pH 7 in the presence of CaCl₂. Conclusions ArtE2 showed enhanced antibacterial activity relative to native E2 against the strains tested. Evaluation against a broader and more clinically diverse bacterial panel is warranted.
No takes yet. Share an insight, caveat, or question.
Portieles et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: